Ethema Health Corporation
Ethema Health Corporation (GRST) Financial Performance & Income Statement Overview
Analyze Ethema Health Corporation (GRST) financial statements (income, balance sheet, and cash flow) across both yearly and quarterly periods.
Ethema Health Corporation (GRST) Income Statement & Financial Overview
View the income breakdown for Ethema Health Corporation GRST across both annual and quarterly reports.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $1.47M | $1.76M | $1.49M | $1.30M |
| Cost of Revenue | $0.00 | $392772.00 | $274130.00 | $118890.00 |
| Gross Profit | $1.47M | $1.37M | $1.22M | $1.18M |
| Gross Profit Ratio | $1.00 | $0.78 | $0.82 | $0.91 |
| R&D Expenses | $0.00 | $0.00 | $0.00 | $0.00 |
| SG&A Expenses | $656035.00 | $1.52M | $1.66M | $1.42M |
| Operating Expenses | $1.57M | $2.09M | $1.77M | $1.53M |
| Total Costs & Expenses | $1.57M | $2.48M | $1.77M | $1.53M |
| Interest Income | $428.00 | $766.00 | $523.00 | $575.00 |
| Interest Expense | $334181.00 | $308780.00 | $182154.00 | $156348.00 |
| Depreciation & Amortization | $189130.00 | $186400.00 | $119919.00 | $118890.00 |
| EBITDA | $197566.00 | -$506000.00 | -$163000.00 | -$98970.00 |
| EBITDA Ratio | $0.13 | -$0.29 | -$0.11 | -$0.08 |
| Operating Income | -$103000.00 | -$724000.00 | -$278000.00 | -$229000.00 |
| Operating Income Ratio | -$0.07 | -$0.41 | -$0.19 | -$0.18 |
| Other Income/Expenses (Net) | -$223000.00 | -$277000.00 | -$188000.00 | -$145000.00 |
| Income Before Tax | -$326000.00 | -$1.001M | -$465000.00 | -$374000.00 |
| Income Before Tax Ratio | -$0.22 | -$0.57 | -$0.31 | -$0.29 |
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$326000.00 | -$1.001M | -$363000.00 | -$374000.00 |
| Net Income Ratio | -$0.22 | -$0.57 | -$0.24 | -$0.29 |
| EPS | -$0.00 | -$0.00 | -$0.00 | -$0.00 |
| Diluted EPS | -$0.00 | -$0.00 | -$0.00 | -$0.00 |
| Weighted Avg Shares Outstanding | $7.21B | $7.21B | $3.73B | $3.73B |
| Weighted Avg Shares Outstanding (Diluted) | $7.21B | $7.21B | $3.73B | $3.73B |
The company's financials show resilient growth, with revenue advancing from $1.30M in Q1 2024 to $1.47M in Q4 2024. Gross profit remained healthy with margins at 100% in Q4 2024 compared to 91% in Q1 2024. Operating income hit -$103000.00 last quarter, sustaining a consistent -7% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at $197566.00. Net income rose to -$326000.00, while earnings per share reached -$0.00. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan